Children and infants with a rare neurodegenerative disorder, will undergo a Phase I clinical trial using stem cells at Doernbecher Children’s Hospital, Oregon Health & Science University.兒童和嬰兒患有一種罕見的神經退化性疾病，將進行第一階段臨床試驗利用幹細胞在doernbecher兒童醫院，俄勒岡衛生科學大學。

This trial will test if:這項試驗將檢驗，如果：

1. 1 。 HuCNS-SC(TM), a proprietary human central nervous stem cell product developed by Stem Cells, Inc. is safe or not. hucns鈧（ TM ）是一個專有人體中樞神經幹細胞產品研製的幹細胞公司是安全與否。

2. 2 。 It can slow the progression of two forms of neuronal ceroid lipofuscinosis (NCL).它可以緩慢的進展，這兩種形式的神經元ceroid脂（累托土） 。

NCL is caused due to mutations or changes in the genes responsible for producing certain enzymes.累托土是造成因突變或變化，在基因負責生產某些酶。 Without these enzymes or proteins, material builds up inside brain neurons and other brain cells, causing a rapidly progressive decline in mental and motor function, blindness, seizures and early death.如果沒有這些酶或蛋白物質積聚大腦內的神經元和其他的腦細胞，導致急進下降，心理和運動功能，失明，癲癇和早期死亡。

Dr Robert D Steiner, vice chairman of pediatric research at Doernbecher Children’s Hospital, said that neural stem cell transplantation has never been done before and stem cells will provide an important therapeutic advancement for the children diagnosed with NCL.醫生羅伯特d施泰納副委員長，兒科研究doernbecher兒童醫院表示，神經幹細胞移植已是以前從未和幹細胞將提供一個重要的治療進步，為孩子診斷出累托土。

Co-investigator Nathan Selden commented that the effort of delivering stem cells directly into the human brain is found safe and effective it will be tagged as one of the potential treatment in helping thousands of patients suffering from degenerative brain diseases.聯合調查彌敦道塞爾登評論說，這一努力提供幹細胞直接注入人腦是找到安全而有效的將貼有標籤的一個潛在的治療，幫助成千上萬的病人患有退化性腦疾病。

Up to six children from Oregon or around the country will undergo HuCNS-SC transplantation at Doernbecher.截至6個孩子從俄勒岡州或靠近該國將經歷hucns鈧移植doernbecher 。 Previous studies on mice have shown that HuCNS-SC increases the amount of the missing enzyme, reduces the amount of abnormal material in the brain and prevents the death of some brain cells.以往的研究中對小鼠顯示hucns -增加排污費的數額失踪酶，可減少的金額異常的物質在大腦中，並防止死一些腦細胞。

Stem Cells, Inc. received clearance from the US Food and Drug Administration to initiate a Phase 1 clinical trial of HuCNS-SC in October 2005.幹細胞公司收到手續，由美國食品和藥物管理局展開第一期臨床試驗的hucns -資深大律師在2005年10月。 The company believes this will be the first trial using a purified composition of neural stem cells as a potential therapeutic agent in humans.該公司相信，這將成為第一個試驗計劃，使用純化的組成神經幹細胞是一種潛在的治療劑，在人類。

Link鏈接